Early research (Phase 1)Study completedNCT00004047What this trial is testingChemotherapy in Treating Patients Who Have Hematologic CancerWho this might be right forLeukemiaMyelodysplastic Syndromes Daiichi Sankyo
Testing effectiveness (Phase 2)Study completedNCT00365287What this trial is testingCombination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney CancerWho this might be right forBreast CancerKidney CancerLeukemia+3 more Masonic Cancer Center, University of Minnesota 148
Testing effectiveness (Phase 2)Looking for participantsNCT05601726What this trial is testingFirst-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult PatientsWho this might be right forAcute Myeloid Leukemia, AdultMyelodysplastic Syndromes Advanced BioDesign 36
Testing effectiveness (Phase 2)Looking for participantsNCT06537843What this trial is testingSafety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid LeukemiaWho this might be right forAcute Myeloid Leukemia Hospital Municipal São José 100
Testing effectiveness (Phase 2)Looking for participantsNCT07584889What this trial is testingEfficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic MalignanciesWho this might be right forB Cell LymphomaAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia Shenzhen University General Hospital 10
Testing effectiveness (Phase 2)Study completedNCT00003840What this trial is testingDTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid LeukemiaWho this might be right forLeukemia Wake Forest University Health Sciences
Testing effectiveness (Phase 2)Study completedNCT00006240What this trial is testingPhenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaWho this might be right forLeukemia National Heart, Lung, and Blood Institute (NHLBI)
Not applicableNo Longer AvailableNCT03409081What this trial is testingEarly Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)Who this might be right forAcute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) Mutations Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT00798213What this trial is testingSCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)Who this might be right forLeukemia, Myeloid, AcuteLymphoblastic Leukemia, Acute Merck Sharp & Dohme LLC 29
Early research (Phase 1)Study completedNCT00012376What this trial is testingChemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid CancerWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)+15 more National Cancer Institute (NCI) 35
Early research (Phase 1)Study completedNCT00002818What this trial is testingHigh-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic MalignanciesWho this might be right forDrug/Agent Toxicity by Tissue/OrganLeukemiaLymphoma+1 more Virginia Commonwealth University 15
Early research (Phase 1)Ended earlyNCT05263271What this trial is testingGentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic SyndromeWho this might be right forAcute Myelogenous LeukemiaMyelodysplastic Syndromes Changchun GeneScience Pharmaceutical Co., Ltd. 58
Early research (Phase 1)Ended earlyNCT02781467What this trial is testingA Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)Who this might be right forLeukemia, Myeloid, Acute Celularity Incorporated 10
Testing effectiveness (Phase 2)Study completedNCT03349502What this trial is testingMG4101 for Refractory or Relapsed AMLWho this might be right forAcute Myeloid Leukemia Seoul National University Hospital 11
Early research (Phase 1)Study completedNCT03263637What this trial is testingStudy to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesWho this might be right forRelapsed or Refractory Haematological Malignancies IncludingAcute Myeloid LeukemiaAcute Lymphocytic Leukemia+8 more AstraZeneca 44
Testing effectiveness (Phase 2)Study completedNCT00553202What this trial is testingDonor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous LeukemiaWho this might be right forLeukemia Children's Oncology Group 158
Testing effectiveness (Phase 2)Ended earlyNCT04166929What this trial is testingHaploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDSWho this might be right forAcute Myeloid LeukemiaMyelodysplasia Fondazione Policlinico Universitario Agostino Gemelli IRCCS 6
Early research (Phase 1)Ended earlyNCT06714591What this trial is testingEvaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1Who this might be right forRelapsed/Refractory Acute Myeloid Leukemia SystImmune Inc. 52
Early research (Phase 1)Ended earlyNCT04196010What this trial is testingContinuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid NeoplasmsWho this might be right forMyeloid NeoplasmRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia University of Washington 13
Testing effectiveness (Phase 2)UnknownNCT05055791What this trial is testingEvaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic MalignanciesWho this might be right forAcute Myeloid LeukemiaLymphomaMultiple Myeloma CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 312